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is to characterize patient referrals between urologists and medical oncologists/
hematologists (MOH) following diagnosis of Stage IV disease. METHODS: A retro-
spective analysis of linked Surveillance, Epidemiology, and Endpoints (SEER) – 
Medicare data included patients diagnosed with Stage IV PCa between 1994 and 2002 
(age  65 years). Patients who saw a MOH before the urologist visit were deleted. 
Patients were grouped according to M0/M1 substage. Time to physician visit, in
months (m), was deﬁ ned relative to diagnosis in the base case. RESULTS: Application
of the inclusion and exclusion criteria resulted in 8840 patients (average age 77 years;
81% White; 68% M1 disease). Seventy-four percent of the patients visited a urologist. 
Of these, 33% followed up with a MOH. Of these, 41.5% saw the MOH within 6 m, 
55.7% within 12 m, and 25% waited 24 m. The mean time to MOH visit was 
longer when a patient saw a urologist ﬁ rst, compared to when a patient did not see
a urologist (20.1 m vs. 5.2 m; p  0.0001). M1 patients saw MOH sooner than M0 
patients: 14.1 m vs. 27.5 m; p  0.0001. Qualitative results were similar whether
conditioned for a urologist visit (16.9 m vs. 29 m; p  0.0001) or conditioned for ‘no 
urologist visit’ (4.6 m vs. 11.1 m; p  0.01). CONCLUSIONS: Similar to other studies,
we ﬁ nd that the majority of patients with Stage IV PCa see a urologist post diagnosis.
About a third of patients who see a urologist are referred to a MOH and 25% 
wait more than 2 years to see the MOH. We ﬁ nd that the time to a MOH visit aver-
ages 20 months among those who ﬁ rst see a urologist versus 5 months among those 
who do not.
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OBJECTIVES: To examine epoetin alfa (EPO) and darbepoetin alfa (DARB) drug 
utilization in cancer chemotherapy patients before and after ESA coverage limitations
by the Centers for Medicare and Medicaid Services National Coverage Determination
(NCD). METHODS: Medical claims from the Ingenix Impact National Managed Care
Database were analyzed. Patients included in the study were q18 years, had q1 claim
for cancer, were newly initiated on EPO or DARB, and received chemotherapy during 
ESA treatment. Patients initiating ESA therapy between 8/2006–12/2006 (pre-NCD) 
were compared with those initiating between August 2007–December 2007 (post-
NCD). The number of patients treated, dose per injection, cumulative drug utilization
during the ﬁ rst 16 weeks of therapy, and dose ratio (cumulative dose EPO: DARB) 
were compared between the two groups. RESULTS: A total of 3951 ESA treatment 
episodes were identiﬁ ed (pre-NCD: 3046; post-NCD: 905). Patients in the post-NCD 
group were generally older (pre-NCD: 56.2 years; post-NCD: 58.7 years; p  0.0001) 
than the pre-NCD group. The number of patients receiving ESA in the post-NCD 
relative to pre-NCD period decreased by 61% (from 1057 to 411 patients) for EPO 
and 75% (from 1989 to 494 patients) for DARB. Furthermore, among the subset of 
treated patients in each period, total dose administered per patient within 16 weeks 
of treatment initiation decreased by 20% (Units: pre-NCD 251,902 vs. post-NCD 
200,635) for EPO and 13% (mcg: pre-NCD 917 vs post-NCD 801) for DARB, despite 
stable dose per injection pre- and post-NCD. The EPO: DARB dose ratio was higher 
in the pre-NCD group (274:1) than the post-NCD group (250:1). CONCLUSIONS:
Recent changes to ESA coverage policy appear to have decreased ESA utilization and 
the corresponding EPO: DARB dose ratio. Further research is warranted to assess this
impact on the demand for blood transfusions.
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OBJECTIVES: More and more evidences support the granulocyte-colony stimulating 
factor (G-CSF) use as a primary prophylaxis in breast cancer patients treated with 
high risk of febrile neutropenia(FN). Although National Comprehensive Cancer
Network have the practice guidance, Bureau of National Insurance in Taiwan doesn’t
approve the claim for the indication. The aim of this study was to evaluate the effec-
tiveness of G-CSF for preventive treatment of FN. METHODS: The retrospective 
study was conducted from January 1, 2001 to December 31, 2006. Breast cancer 
patients treated with taxanes-based regimens simultaneously combined with primary 
prophylactic G-CSF were recruited in this study. The three regimens were TEC, FECP
and TE (C, cyclophosphamide; E, epirubicin; F, ﬂ uorouracil; P, paclitaxel; T, docetaxel).
ANOVA and Chi-square were used to analyze the relationship of the decline of inci-
dence of FN by using primary G-CSF prophylaxis between diferent regimens.
RESULTS: Finally,128 patients were eligible in the study. The results show the baseline 
laboratory data of breast cancer patients in TEC group is in normal range compared
to others. However, the laboratory data of TEC group appeared worse than others 
after G-CSF was given at the dose of 5 mg/kg. Under the primary prophylactic G-CSF
policy, the incidence of FN in TEC group was higher than TE groups (4.7% versus 
0.6%), but no FN appeared in FECP regimen. It showed that TEC regimen have 
more bone-marrow suppression effect than others. Our ﬁ nding also indicated a better
results decrease FN by using G-CSF as a prophylaxis as compared to other published 
studies.(episodes of FN in our study were lower than published  2.4% versus 7.5%) 
CONCLUSIONS: The study showed the beneﬁ cial effect of declining the occurrence 
of FN. We hope that the use of primary prophylactic G-CSF should be considered as 
a guideline for clinical practice to improve patient’s quality of life.
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OBJECTIVES: This study evaluated the use of breast cancer (BC) screening or diag-
nostic procedures in postmenopausal women (PMW) initiating osteoporosis (OP) 
medications. METHODS: Women 50 years and older with at least one claim for ral-
oxifene (RLX), bisphosphonates (BIS) or calcitonin (CT) in 2005 or 2006 and continu-
ous enrollment in the previous and subsequent 12 months were identiﬁ ed in a large 
national commercial and Medicare claims database. PMW initiating RLX were com-
pared to PMW initiating BIS and CT in terms of BC screening or diagnostic procedures 
(mammogram, breast MRI, ultrasound, breast biopsy) as well as age, provider spe-
cialty, fractures, BMD screening and comorbidities. RESULTS: Treatment-naive PMW 
aged 55–59 years were more likely to initiate RLX than other age groups (Adjusted
Odds Ratio (AOR)  1.864 vs. aged 70 years; p  0.0001). RLX patients were 
younger than BIS and CT patients (mean age 63 years [RLX], 66 years [BIS], 72 years
[CT]; p  0.05). Treatment-naive PMW with at least one BC screening or diagnostic 
claim within the 12 month pre-period were more likely to initiate on RLX than those 
with none during the same period (AOR  1.183, p  0.0001). Treatment-naïve RLX 
patients were more likely to have had BC screening or diagnostic procedures in the 
12 months prior to therapy initiation than treatment-naïve BIS or CT patients (RLX 
61%, BIS 57%, CT 41%; p  0.05) and were more likely to have an increased fre-
quency of mammograms in the 12 months after therapy initiation (RLX 18%, BIS
16%, CT 15%, p  0.05). CONCLUSIONS: In this study population, PMW who 
initiated RLX treatment were more likely to have had BC screening or diagnostic 
procedures prior to initiating therapy than PMW on other OP medications. This data
suggests that PMW who initiate on RLX may have greater perceived or actual risks
for BC than PMW who initiate on other therapies.
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OBJECTIVES: Preoperative or postoperative radiotherapy has been used to decrease 
local recurrence and thereby improve survival. Previous studies comparing these two 
types of treatments have given conﬂ icting results. The study aims to compare the efﬁ -
ciency of preoperative versus postoperative radiotherapy in terms of survival for 
resectable colorectal cancer (Stage II and III). METHODS: The study has been carried
out on patients with resectable colorectal cancer in stage II and III. It is based on the
data recorded by National Cancer institute, Surveillance Epidemiology and End
Results (SEER) 17 registries data between year 1999 and 2005. Survival analysis was 
used to assess the patients exposed to radiotherapy as an adjuvant therapy before or
after surgery and a comparison of survival time in between the two groups was done 
using the log rank test. RESULTS: A total of 12,134 patients were subjected to radio-
therapy as adjuvant therapy. Out of which 7481 were administered with radiation 
after surgery and 4653 patients with radiation prior to surgery were taken into con-
sideration for the study. Patients who have been administered radiotherapy after 
surgery have shown longer survival time (43 months) than patients administered with
radiotherapy before surgery (33 months) (p  0.000). The survival time difference may
also be attributable to the Stage of the cancer. The survival time for Stage III patients 
receiving radiation after surgery is longer than patients administered with radiation 
before surgery (43 months vs. 29 months; p  0.000). No signiﬁ cant survival difference 
was observed in Stage II patients. CONCLUSIONS: The study should assist the clini-
cian in forming a preliminary opinion for further investigations pertaining to the 
sequence of radiation with surgery as adjuvant therapy for resectable colorectal cancer. 
Further studies should also investigate the inﬂ uence of demographics, dose of radiation
and co-morbidity on survival time in the resectable colorectal cancer cases.
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OBJECTIVES: Screening mammography is regarded as the gold standard for identify-
ing breast cancer in early stages. The American Cancer Society (ACS) recommends
annual screening mammography for all women q40 years of age with an average risk
of breast cancer for early cancer detection. Mammography rates generally tend to be 
lower among indigent women. The purpose of this study was to determine annual 
mammography screening trends from 2000 to 2005 among fee-for-service women 
recipients enrolled in a state Medicaid program based on demographic and geographic 
characteristics. METHODS: Fee-for-service medical claims for all women enrolled in 
the state Medicaid program from January 1, 2000 to December 31, 2005 were used.
